Insights into the development of < sup > 99m < /sup > Tc-radioligands for serotonergic receptors imaging: Synthesis, labeling, In vitro, and In vivo studies

Eur J Med Chem. 2024 Mar 23;270:116349. doi: 10.1016/j.ejmech.2024.116349. Online ahead of print.ABSTRACTSerotonergic (5-hydroxytryptamine; 5-HT) receptors play critical roles in neurological and psychological disorders such as schizophrenia, anxiety, depression, and Alzheimer's diseases. Therefore, it is particularly important to develop novel radioligands or modify the existing ones to identify the serotonergic receptors involved in psychiatric disorders. Among the 16 subtypes of serotonergic systems, only technetium-99m based radiopharmaceuticals have been evaluated for serotonin-1A (5-HT1A), serotonin-2A (5-HT2A), 5-HT1A/7 heterodimers and serotonin receptor neurotransmitter (SERT). This review focuses on recent efforts in the design, synthesis and evaluation of 99mTc-radioligands used for single photon emission computerized tomography (SPECT) imaging of serotonergic (5-HT) receptors. Additionally, the discussion will cover aspects such as chemical structure, in vitro/vivo stability, affinity toward serotonin receptors, blood-brain barrier permeation (BBB), and biodistribution study.PMID:38555856 | DOI:10.1016/j.ejmech.2024.116349
Source: European Journal of Medicinal Chemistry - Category: Chemistry Authors: Source Type: research